Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline

Giuseppe Miscio, Giulia Paroni, Paola Bisceglia, Carolina Gravina, Maria Urbano, Madia Lozupone, Carla Piccininni, Michele Prisciandaro, Grazia Ciavarella, Antonio Daniele, Antonello Bellomo, Francesco Panza, Lazzaro Di Mauro, Antonio Greco, Davide Seripa

Research output: Contribution to journalArticle

Abstract

Introduction: Over the last decade, the spread of next-generation sequencing technology along with the rising cost in health management in national health systems has led to widespread use/abuse of pharmacogenetic tests (PGx) in the practice of many clinical disciplines. However, given their clinical significance, it is important to standardize these tests for having an interaction with the clinical analysis laboratory (CAL), in which a PGx service can meet these requirements. Areas covered: A diagnostic test must meet the criteria of reproducibility and validity for its utility in the clinical routine. This present review mainly describes the utility of introducing PGx tests in the CAL routine to produce correct results useful for setting up personalized drug treatments. Expert opinion: With a PGx service, CALs can provide the right tool to help clinicians to make better choices about different categories of drugs and their dosage and to manage the economic impact both in hospital-based settings and in National Health Services, throughout electronic health records. Advances in PGx also allow a new approach for pharmaceutical companies in order to improve drug development and clinical trials. As a result, CALs can achieve a powerful source of epidemiological, clinical, and research findings from PGx tests.

Original languageEnglish
Pages (from-to)751-765
Number of pages15
JournalExpert opinion on drug metabolism & toxicology
Volume15
Issue number9
DOIs
Publication statusPublished - Sep 1 2019

Fingerprint

Clinical laboratories
Pharmacogenetics
Pipelines
Health
Research
Pharmaceutical Preparations
Drug therapy
Electronic Health Records
Expert Testimony
National Health Programs
Routine Diagnostic Tests
Health Care Costs
Economics
Clinical Trials
Technology
Costs
Industry

Keywords

  • adverse drug reactions
  • Clinical laboratory analysis
  • pharmacogenetics
  • therapeutic failure

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

Pharmacogenetics in the clinical analysis laboratory : clinical practice, research, and drug development pipeline. / Miscio, Giuseppe; Paroni, Giulia; Bisceglia, Paola; Gravina, Carolina; Urbano, Maria; Lozupone, Madia; Piccininni, Carla; Prisciandaro, Michele; Ciavarella, Grazia; Daniele, Antonio; Bellomo, Antonello; Panza, Francesco; Di Mauro, Lazzaro; Greco, Antonio; Seripa, Davide.

In: Expert opinion on drug metabolism & toxicology, Vol. 15, No. 9, 01.09.2019, p. 751-765.

Research output: Contribution to journalArticle

Miscio, Giuseppe ; Paroni, Giulia ; Bisceglia, Paola ; Gravina, Carolina ; Urbano, Maria ; Lozupone, Madia ; Piccininni, Carla ; Prisciandaro, Michele ; Ciavarella, Grazia ; Daniele, Antonio ; Bellomo, Antonello ; Panza, Francesco ; Di Mauro, Lazzaro ; Greco, Antonio ; Seripa, Davide. / Pharmacogenetics in the clinical analysis laboratory : clinical practice, research, and drug development pipeline. In: Expert opinion on drug metabolism & toxicology. 2019 ; Vol. 15, No. 9. pp. 751-765.
@article{70d7fc7a5cc8485cb0346a1b10b60639,
title = "Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline",
abstract = "Introduction: Over the last decade, the spread of next-generation sequencing technology along with the rising cost in health management in national health systems has led to widespread use/abuse of pharmacogenetic tests (PGx) in the practice of many clinical disciplines. However, given their clinical significance, it is important to standardize these tests for having an interaction with the clinical analysis laboratory (CAL), in which a PGx service can meet these requirements. Areas covered: A diagnostic test must meet the criteria of reproducibility and validity for its utility in the clinical routine. This present review mainly describes the utility of introducing PGx tests in the CAL routine to produce correct results useful for setting up personalized drug treatments. Expert opinion: With a PGx service, CALs can provide the right tool to help clinicians to make better choices about different categories of drugs and their dosage and to manage the economic impact both in hospital-based settings and in National Health Services, throughout electronic health records. Advances in PGx also allow a new approach for pharmaceutical companies in order to improve drug development and clinical trials. As a result, CALs can achieve a powerful source of epidemiological, clinical, and research findings from PGx tests.",
keywords = "adverse drug reactions, Clinical laboratory analysis, pharmacogenetics, therapeutic failure",
author = "Giuseppe Miscio and Giulia Paroni and Paola Bisceglia and Carolina Gravina and Maria Urbano and Madia Lozupone and Carla Piccininni and Michele Prisciandaro and Grazia Ciavarella and Antonio Daniele and Antonello Bellomo and Francesco Panza and {Di Mauro}, Lazzaro and Antonio Greco and Davide Seripa",
year = "2019",
month = "9",
day = "1",
doi = "10.1080/17425255.2019.1658742",
language = "English",
volume = "15",
pages = "751--765",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Taylor and Francis Ltd.",
number = "9",

}

TY - JOUR

T1 - Pharmacogenetics in the clinical analysis laboratory

T2 - clinical practice, research, and drug development pipeline

AU - Miscio, Giuseppe

AU - Paroni, Giulia

AU - Bisceglia, Paola

AU - Gravina, Carolina

AU - Urbano, Maria

AU - Lozupone, Madia

AU - Piccininni, Carla

AU - Prisciandaro, Michele

AU - Ciavarella, Grazia

AU - Daniele, Antonio

AU - Bellomo, Antonello

AU - Panza, Francesco

AU - Di Mauro, Lazzaro

AU - Greco, Antonio

AU - Seripa, Davide

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Introduction: Over the last decade, the spread of next-generation sequencing technology along with the rising cost in health management in national health systems has led to widespread use/abuse of pharmacogenetic tests (PGx) in the practice of many clinical disciplines. However, given their clinical significance, it is important to standardize these tests for having an interaction with the clinical analysis laboratory (CAL), in which a PGx service can meet these requirements. Areas covered: A diagnostic test must meet the criteria of reproducibility and validity for its utility in the clinical routine. This present review mainly describes the utility of introducing PGx tests in the CAL routine to produce correct results useful for setting up personalized drug treatments. Expert opinion: With a PGx service, CALs can provide the right tool to help clinicians to make better choices about different categories of drugs and their dosage and to manage the economic impact both in hospital-based settings and in National Health Services, throughout electronic health records. Advances in PGx also allow a new approach for pharmaceutical companies in order to improve drug development and clinical trials. As a result, CALs can achieve a powerful source of epidemiological, clinical, and research findings from PGx tests.

AB - Introduction: Over the last decade, the spread of next-generation sequencing technology along with the rising cost in health management in national health systems has led to widespread use/abuse of pharmacogenetic tests (PGx) in the practice of many clinical disciplines. However, given their clinical significance, it is important to standardize these tests for having an interaction with the clinical analysis laboratory (CAL), in which a PGx service can meet these requirements. Areas covered: A diagnostic test must meet the criteria of reproducibility and validity for its utility in the clinical routine. This present review mainly describes the utility of introducing PGx tests in the CAL routine to produce correct results useful for setting up personalized drug treatments. Expert opinion: With a PGx service, CALs can provide the right tool to help clinicians to make better choices about different categories of drugs and their dosage and to manage the economic impact both in hospital-based settings and in National Health Services, throughout electronic health records. Advances in PGx also allow a new approach for pharmaceutical companies in order to improve drug development and clinical trials. As a result, CALs can achieve a powerful source of epidemiological, clinical, and research findings from PGx tests.

KW - adverse drug reactions

KW - Clinical laboratory analysis

KW - pharmacogenetics

KW - therapeutic failure

UR - http://www.scopus.com/inward/record.url?scp=85072361962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072361962&partnerID=8YFLogxK

U2 - 10.1080/17425255.2019.1658742

DO - 10.1080/17425255.2019.1658742

M3 - Article

C2 - 31512953

AN - SCOPUS:85072361962

VL - 15

SP - 751

EP - 765

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 9

ER -